logo
  

JDS Uniphase Swings To Q1 Loss, But Tops View

Communications solutions provider JDS Uniphase Corp. (JDSU), Wednesday posted a loss for the first quarter, turning around from a profit last year, as revenues grew while operating costs increased. Nevertheless, adjusted earnings for the quarter improved from a year ago and came in ahead of analysts' estimates, as did revenues.

The Milpitas, California-based company reported first-quarter net loss of $9.7 million or $0.04 per share, compared with net income of $0.3 million or break even per share last year.

Adjusted net income for the quarter rose to $33.8 million or $0.14 per share from $30.2 million or $0.13 per share last year. On average, 15 analysts polled by Thomson Reuters expected the company to earn $0.10 per share for the quarter. Analysts' estimates typically exclude special items.

Net revenues for the quarter rose 1.1 percent to $433.6 million from $429.0 million a year ago. Analysts had a consensus revenue estimate of $416.7 million for the quarter.

Gross margins improved to 46.0 percent from 43.2 percent last year.

"JDSU's strategy to diversify in non-telecom markets drove a solid first quarter as we exceeded revenue and EPS guidance and saw sequential growth in solutions for the enterprise and commercial lasers markets," said Chief Executive Tom Waechter.

Moving ahead, the company expects second-quarter adjusted earnings of $0.15, plus or minus $0.03 and adjusted revenues to be $445 million, plus or minus $12 million. Analysts currently estimate earnings of $0.17 per share on revenues of $445.9 million for the quarter.

Last month, JDS Uniphase announced a plan to split itself into two publicly traded companies, with one business focusing on optical products and the other on networking.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT